Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Moderna Inc MRNA

Healthcare Biotechnology

Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular... see more

Add To Watchlist

Recent & Breaking News (NDAQ:MRNA)

Moderna's COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study

Business Wire November 16, 2020

Moderna Announces Longer Shelf Life for its COVID-19 Vaccine Candidate at Refrigerated Temperatures

Business Wire November 16, 2020

Swissmedic Begins Rolling Review of Moderna's mRNA Vaccine Against COVID-19 (mRNA-1273)

Business Wire November 13, 2020

U.S. Stocks Mixed in Early Going

Livemoney November 12, 2020

Moderna Has Completed Case Accrual for First Planned Interim Analysis of its mRNA Vaccine Against COVID-19 (mRNA-1273)

Business Wire November 11, 2020

Moderna Announces Clinical Updates on Personalized Cancer Vaccine Program

Business Wire November 11, 2020

2nd Annual Gabelli Funds - Columbia Business School Healthcare Symposium (Virtual) - Friday, November 13, 2020

Business Wire November 2, 2020

Moderna to Present at Upcoming Investor Conferences in November 2020

Business Wire November 2, 2020

Moderna Named Top Employer by Science for Sixth Consecutive Year

Business Wire October 30, 2020

Stocks Try to Recover from Worst Selloff in Months

Livemoney October 29, 2020

Moderna Reports Third Quarter 2020 Financial Results and Provides Business Updates

Business Wire October 29, 2020

Moderna Partners with Takeda and the Government of Japan to Supply 50 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273) to Japan

Business Wire October 29, 2020

UK Medicines and Healthcare products Regulatory Agency Begins Rolling Review of Moderna's mRNA Vaccine Against COVID-19 (mRNA-1273)

Business Wire October 27, 2020

Moderna Announces Supply Agreement with the Ministry of Public Health to Supply Qatar with mRNA Vaccine Against COVID-19 (mRNA-1273)

Business Wire October 26, 2020

Moderna Completes Enrollment of Phase 3 COVE Study of mRNA Vaccine Against COVID-19 (mRNA-1273)

Business Wire October 22, 2020

Dow Set to Pop as Stimulus Seen as Pending

Livemoney October 20, 2020

2nd Annual Gabelli Funds - Columbia Business School Healthcare Symposium (Virtual)

Business Wire October 19, 2020

Moderna to Report Third Quarter 2020 Financial Results on Thursday, October 29, 2020

Business Wire October 15, 2020

Moderna Receives Confirmation of Eligibility for Submission of Marketing Authorization Application to the European Medicines Agency for mRNA Vaccine Against COVID-19 (mRNA-1273)

Business Wire October 14, 2020

Moderna Announces Initiation of Rolling Submission to Health Canada for mRNA Vaccine Against COVID-19 (mRNA-1273)

Business Wire October 13, 2020